Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Preferred Dividend Payments (2021)

Zevra Therapeutics' Preferred Dividend Payments history spans 1 years, with the latest figure at $16.9 million for Q2 2021.

  • For Q2 2021, Preferred Dividend Payments changed N/A year-over-year to $16.9 million; the TTM value through Mar 2022 reached $16.9 million, down 54.87%, while the annual FY2021 figure was $54.3 million, N/A changed from the prior year.
  • Preferred Dividend Payments reached $16.9 million in Q2 2021 per ZVRA's latest filing, down from $37.4 million in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $37.4 million in Q1 2021 to a low of $16.9 million in Q2 2021.